



# Fluoxetine-Associated Sleep Disorders-Report of Two Cases and Literature Review

## Fluoksetin Kaynaklı Uyku Bozuklukları: İki Olgu Sunumu ve Literatür Derlemesi

© Leyla Köse Leba, © Aylin Bican Demir\*

Necmettin Erbakan University Meram Medical Faculty, Department of Neurology, Konya, Turkey

\*Bursa Uludağ University Faculty of Medicine, Department of Neurology, Bursa, Turkey

### Abstract

Narcolepsy is a condition characterised by excessive daytime sleepiness, cataplexy, hypnagogic hallucination and sleep paralysis. Sleep-related eating disorder (SRED) is a parasomnia that occurs while sleeping and manifests itself as paroxysmal episodes of involuntary eating and/or drinking. Both sleep disorders often occur as primary conditions. Sleep disorders secondary to medical treatment less often occur. This report presents the case of a patient with narcolepsy and another with SRED as a result of anamnesis and polysomnography. These sleep disorders are due to recently initiated fluoxetine treatment. Sleep disorder occurring as secondary to medication has been ignored because it has eluded the clinicians.

**Keywords:** Narcolepsy, sleep-related eating disorder, fluoxetine, SRED, PSG

### Öz

Narkolepsi; gündüz aşırı uyku hali, katapleksi, hipnagogik halüsinasyon, uyku paralizisi ile karakterize bir hastalıktır. Uyku ile ilgili yeme bozukluğu (SRED); uyku sırasında ortaya çıkan, paroksizmal, istem dışı yemek yeme ve/veya içme epizodları ile seyreden bir parasomni tablosudur. Her iki uyku bozukluğu da sıklıkla primer olarak ortaya çıkmaktadır. Medikal tedaviye sekonder olarak ortaya çıkan olgu daha nadirdir. Bizim sunduğumuz yazıda, anamnez ve polisomnografi incelemesi sonucunda bir hastada narkolepsi, diğer hastada SRED tanıları düşünüldü ve bu durumların yeni başlanan fluoksetin tedavisine sekonder olduğu kararına varıldı. İlaça sekonder oluşan uyku bozukluğu klinisyenler tarafından aklı gelmediği ve sorgulanmadığı için ihmal edilmektedir.

**Anahtar Kelimeler:** Narkolepsi, uyku ile ilişkili yeme bozukluğu, fluoksetin, SRED, PSG

### Introduction

#### Narcolepsy

Narcolepsy is a sleep disorder occurring with 90-95% loss of hypocretin neurons (1) and is mostly seen between 10 and 25 years. It is a disease characterized by excessive daytime sleepiness (EDS), cataplexy, hypnagogic hallucination, and sleep paralysis. It interrupts patients' sleep. Although they have no problem with drifting into sleep, maintaining sleep is difficult for them (2).

EDS is the main symptom and the most common reason of the sleep disability. It cannot be prevented during the day. Repeated episodes of sleep attacks take a short time and they are relaxing. Cataplexy is defined as a repetitive sudden muscle tone loss without loss of consciousness and often takes less than 2 minutes. Hypnagogic hallucinations are accepted as an

experience of vivid like dreams while drifting into sleep. Sleep paralysis is characterized with temporary muscle paralysis while passing awakening from sleep (2,3).

It is required in order to diagnose that sleep latency should be 8 minutes or less on multiple sleep latency test (MSLT) and at least 2 sleep-onset REM (SOREM) periods should be experienced at the beginning of sleep.

SOREM observed within the first 15 minutes on polysomnography (PSG) can substitute one of the SOREM on MSLT. It is referred to as "type 2" in the presence of cataplexy or when hypocretin-1 level is detected as  $\leq 110$  pg/mL in cerebrospinal fluid (4). It is evaluated as "type-2" if hypocretin level is normal and cataplexy does not accompany it.

#### Sleep-Related Eating Disorder (SRED)

Parasomnias are undesirable motor, verbal or behavioral cases occurring during any stage of sleep, including while drifting

**Address for Correspondence/Yazışma Adresi:** MD Leyla Köse Leba, Necmettin Erbakan University Meram Medical Faculty, Department of Neurology, Konya, Turkey

**Phone:** +90 533 724 84 07 **E-mail:** leylakos\_e@hotmail.com **ORCID-ID:** orcid.org/0000-0002-5989-6548

**Received/Geliş Tarihi:** 16.02.2021 **Accepted/Kabul Tarihi:** 28.04.2021

©Copyright 2021 by Turkish Sleep Medicine Society / Journal of Turkish Sleep Medicine published by Galenos Publishing House.






Figure 3. Sleep-onset REM sample and hypnogram




Figure 4. EEG sample performed on the following day and 3/5 REM hypnogram

SOREM: Sleep-onset REM, EEG: Electroencephalography

## Discussion

Parasomnia and narcolepsy attacks, other sleep disorders, in the first place sleep deprivation, fragmented sleep architecture, stress, and sleep apnea can be triggered by environmental and endogenous stimulus like drug, alcohol or substance use (5,6).

Narcolepsy and SRED can also be secondary to medical treatment. It may be right using terminologically secondary narcolepsy or SRED for these cases (4). PSG and MSLT should definitely be performed on a patient considered with narcolepsy. PSG is required in order to research other sleep disorders underlying NREM parasomnia cases starting in adult age group.

Medical agents related to SRED are benzodiazepines, benzodiazepine receptor agonists, mirtazapine, risperidone,

quetiapine, lithium, and anticholinergic drugs (7). Narcolepsy cases developing after vaccine and interferon treatment have also been reported.

It is known that selective serotonin reuptake inhibitors (SSRI) can reduce sleep quality with the activation of serotonergic 5-HT<sub>2</sub> receptors.

SSRI can put REM period back, even repress. It can also disrupt sleep continuity and reduce sleep efficiency (8). It is revealed that insomnia and somnolence complaints are frequent in patients treated with SSRI (9).

It is known that SSRI induces sleep bruxism and REM sleep behavior disorder (8,10). Fluoxetine is a commonly used SSRI. It is usually used in obsessive-compulsive disorder, panic attack, and depression treatment (11). It has an important role in narcolepsy treatment, particularly in reducing cataplexy. It is reported that cataplexy attacks increase with the rapid discontinuation of the medication (12). It is pointed out that monkeys treated with fluoxetine have sleep fragmentation (13). It is also known that sleep bruxism is triggered with fluoxetine usage (14,15).

Narcolepsy or SRED case revealing as a result of fluoxetine usage is not reported in literature. Our cases are remarkable due to the fact that one of them is narcolepsy developing secondarily after fluoxetine, and the other one is SRED. In both patients, sleep disorder has started in adulthood and there is no another detected sleep disorder on PSG. Disappearing of the complaints completely with the discontinuation of the medication supports the diagnosis. Even though, there is a role of fluoxetine on narcolepsy treatment, it should be kept in mind that it can trigger some sleep disorders like bruxism and parasomnia.

## Conclusion

As a consequence, these two cases have been presented in order to draw attention to the sleep disorders triggered by fluoxetine and to lay emphasis on whether there is a recently initiated medication or not before diagnosing primary sleep disorder.

## Ethics

Peer-review: Externally peer-reviewed.

## Authorship Contributions

Concept: L.K.L., A.B.D., Design: L.K.L., A.B.D., Data Collection or Processing: L.K.L., A.B.D., Analysis or Interpretation: L.K.L., A.B.D., Literature Search: L.K.L., A.B.D., Writing: L.K.L., A.B.D.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 2000;27:469-74.
2. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. *Lancet* 2007;369:499-511.

3. Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. *J Neurosci* 2012;32:12305-11.
4. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest* 2014;146:1387-94.
5. Broughton RJ, Shimizu T. Sleep-related violence: a medical and forensic challenge. *Sleep* 1995;18:727-30.
6. Pressman MR. Factors that predispose, prime and precipitate NREM parasomnias in adults: Clinical and forensic implications. *Sleep Med Rev* 2007;11:5-30.
7. Vinai P, Ferri R, Ferini-Strambi L, Cardetti S, Anelli M, Vallauri P, Ferrato N, Zucconi M, Carpegna G, Manconi M. Defining the borders between Sleep-Related Eating Disorder and Night Eating Syndrome. *Sleep Med* 2012;13:686-90.
8. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and Antidepressant Treatment. *Curr Pharm Des* 2012;18:5802-17.
9. Thompson C. Onset of action of antidepressants: results of different analyses. *Hum Psychopharmacol* 2002;17(Suppl 1):S27-32.
10. Wilson S, Argyropoulos S. Antidepressants and sleep. *Drugs* 2005;65:927-47.
11. Stoyek MR, Jonz MG, Smith FM, Croll RP. Distribution and chronotropic effects of serotonin in the zebrafish heart. *Auton Neurosci* 2017;206:43-50.
12. Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. *Neurology* 2005;65:967-8.
13. Golub MS, Hogrefe CE. Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine. *Neurotoxicol Teratol* 2016;55:1-7.
14. Çolak Sivri R, Akça ÖF. Buspirone in the Treatment of Fluoxetine-Induced Sleep Bruxism. *J Child Adolesc Psychopharmacol* 2016;26:762-3.
15. Akbaş B, Bilgiç A. Fluoxetine-Induced Sleep Bruxism Rapidly Treated With Once-Nightly Dosing of Buspirone in a 6-Year-Old Girl. *Clin Neuropharmacol* 2018;41:197-8.